Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
June 30, 2026 62.14%
March 31, 2026 55.11%
December 31, 2025 -1.46%
September 30, 2025 87.76%
June 30, 2025 89.92%
March 31, 2025 75.83%
December 31, 2024 85.01%
September 30, 2024 82.45%
June 30, 2024 23.08%
March 31, 2024 57.51%
December 31, 2023 -26.89%
September 30, 2023
June 30, 2023 70.71%
March 31, 2023 93.51%
September 30, 2022 -77.12%
June 30, 2022 -81.03%
March 31, 2022 -47.34%
December 31, 2021 74.64%
September 30, 2021 79.21%
June 30, 2021 82.04%
March 31, 2021 76.41%
December 31, 2020 74.11%
September 30, 2020 81.71%
June 30, 2020 56.48%
March 31, 2020 75.70%
Date Value
December 31, 2019 80.33%
September 30, 2019 93.31%
June 30, 2019 77.56%
March 31, 2019 77.96%
December 31, 2018 79.45%
September 30, 2018 77.76%
June 30, 2018 86.19%
March 31, 2018 81.63%
December 31, 2017 84.22%
September 30, 2017 82.91%
June 30, 2017 82.71%
March 31, 2017 82.20%
December 31, 2016 83.11%
September 30, 2016 76.92%
June 30, 2016 73.78%
March 31, 2016 77.12%
December 31, 2015 77.73%
September 30, 2015 76.68%
June 30, 2015 78.40%
March 31, 2015 76.38%
December 31, 2014 79.05%
September 30, 2014 74.17%
June 30, 2014 75.82%
March 31, 2014 70.19%
December 31, 2013 83.43%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 54.97%
Corcept Therapeutics, Inc. 98.41%
Veru, Inc. --
Johnson & Johnson 73.00%
Eli Lilly & Co. 85.78%

Gross Profit Margin (Quarterly) Related Metrics